Trial Profile
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb18087 in Subjects With Advanced Neuroendocrine and Gastrointestinal Stromal Tumors (DUET-1)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Tidutamab (Primary)
- Indications Gastrointestinal stromal tumours; Neuroendocrine tumours
- Focus Adverse reactions
- Sponsors Xencor
- 06 May 2022 Status changed from active, no longer recruiting to completed.
- 08 Nov 2021 According to a Xencor media release, updated clinical results from the study were presented during the North American Neuroendocrine Tumor Society's 2021 Multidisciplinary NET Medical Virtual Symposium (NANETS).
- 03 Nov 2021 According to a Xencor media release, results from this trial will be presented during the North American Neuroendocrine Tumor Society's 2021 Multidisciplinary NET Medical Virtual Symposium (NANETS).